Jiangsu Hengrui Medicine's (SHA:600276) unit, Guangdong Hengrui Pharmaceutical, will conduct clinical trials on HRS-9813 capsules after receiving approval from China's National Medical Products Administration, according to a Shanghai Stock Exchange filing on Tuesday.
The pharmaceutical company will trial the drug as a treatment for idiopathic pulmonary fibrosis.
The company invested 98.3 million yuan into the research and development of the drug, the filing said.
Hengrui's shares slipped less than 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments